Chimeric antigen receptor T-cell therapy, also called CAR-T therapy, is the type of treatment in which a patient's T cells have been genetically engineered to produce chimeric antigen receptor (CAR) T-cells which are used to recognize cancer cells to more effectively target and destroy them. CARs are proteins that allow the T cells to recognize an antigen on specific tumor cells.
The global market for the CAR-T Cell Therapy Market is primarily driven by the growing prevalence of cancer coupled with high demand for an effective treatment for cancer. However, the stringent regulations, side effects leading to neurological problems coupled with the high cost of treatment may hinder market progress.
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
